Αποτελέσματα Αναζήτησης
14 Δεκ 2023 · This topic review will cover the use of adjuvant HER2-directed therapy plus chemotherapy in patients with HER2-positive, early-stage breast cancer (stage I to III).
- Cameron D, Piccart-Gebhart Mj, Gelber Rd, Et Al. 11 Years' Follow-Up of Trastuzumab After Adjuvant Chemotherapy in HER2-positive Early Breast Cancer: Final Analysis of The HERceptin Adjuvant (Hera) Trial. Lancet 2017; 389:1195
After a median follow-up of 11 years (IQR 10·09-11·53),...
- Martin M, Holmes Fa, Ejlertsen B, Et Al. Neratinib After Trastuzumab-Based Adjuvant Therapy in HER2-positive Breast Cancer (ExteNET): 5-Year Analysis of a Randomised, Double-Blind, Placebo-Controlled, Phase 3 Trial. Lancet Oncol 2017; 18:1688
The estimates of the 3-year rates of invasive-disease-free...
- Curigliano G, Viale G, Bagnardi V, Et Al. Clinical Relevance of Her2 Overexpression/Amplification in Patients With Small Tumor Size and Node-Negative Breast Cancer. J Clin Oncol 2009; 27:5693
This site uses cookies. By continuing to browse this site...
- Bowles Ej, Wellman R, Feigelson Hs, Et Al. Risk of Heart Failure in Breast Cancer Patients After Anthracycline and Trastuzumab Treatment: a Retrospective Cohort Study. J Natl Cancer Inst 2012; 104:1293
RESULTS Among 12 500 women (mean age = 60 years, range =...
- Joensuu H, Kellokumpu-Lehtinen Pl, Bono P, Et Al. Adjuvant Docetaxel Or Vinorelbine With Or Without Trastuzumab for Breast Cancer. N Engl J Med 2006; 354:809
The primary end point was recurrence-free survival. RESULTS...
- Noone Am, Cronin Ka, Altekruse Sf, Et Al. Cancer Incidence and Survival Trends by Subtype Using Data From The Surveillance Epidemiology and End Results Program, 1992-2013. Cancer Epidemiol Biomarkers Prev 2017; 26:632
1 PubMed | TI Cancer Incidence and Survival Trends by...
- Earl Hm, Hiller L, Vallier Al, Et Al. 6 Versus 12 Months of Adjuvant Trastuzumab for HER2-positive Early Breast Cancer (Persephone): 4-Year Disease-Free Survival Results of a Randomised Phase 3 Non-Inferiority Trial. Lancet 2019; 393:2599
The primary endpoint was disease-free survival, analysed by...
- Pivot X, Gligorov J, Müller V, Et Al. Preference for Subcutaneous Or Intravenous Administration of Trastuzumab in Patients With HER2-positive Early Breast Cancer (PrefHer): an Open-Label Randomised Study. Lancet Oncol 2013; 14:962
This site uses cookies. By continuing to browse this site...
- Cameron D, Piccart-Gebhart Mj, Gelber Rd, Et Al. 11 Years' Follow-Up of Trastuzumab After Adjuvant Chemotherapy in HER2-positive Early Breast Cancer: Final Analysis of The HERceptin Adjuvant (Hera) Trial. Lancet 2017; 389:1195
In high-risk patients, systemic chemotherapy is generally recommended. There are several standard chemotherapy options, typically containing both an anthracycline and a taxane. In the United States, doxorubicin and cyclophosphamide for 4 cycles followed by paclitaxel for 4 cycles (AC-T) is a common regimen.
1 Μαΐ 2018 · Dose-Dense AC (DD-AC, Doxorubicin + Cyclophosphamide) + TH (Taxol® + Herceptin®) is a Chemotherapy Regimen for Breast Cancer - early stage. How does Dose-Dense AC + TH work? Doxorubicin, cyclophosphamide, and paclitaxel are designed to kill or slow the growth of cancer cells.
17 Αυγ 2015 · The study included 5,351 patients with node-positive breast cancer to receive four cycles of AC followed by four cycles of docetaxel (sequential AC-D), four cycles of doxorubicin and docetaxel (AD), or four cycles of doxorubicin, cyclophosphamide, and docetaxel (concurrent DAC).
20 Μαΐ 2024 · Evidence supporting unchanged recommendations and sections on cost implications and more are found in the full guideline publication, and apply to this Rapid Update. 1 Additionally, for guideline tools and resources, including a complete summary table, visit www.asco.org/breast-cancer-guidelines.
7 Δεκ 2022 · The following material represents a subset of chemotherapy and immunotherapy regimens that are used for the treatment of patients with breast cancer, both in the adjuvant and neoadjuvant settings.
19 Ιουν 2024 · With a primary endpoint of 5-year iDFS, the investigators were able to demonstrate considerable improvements to iDFS for those on a trastuzumab-containing regimen (AC-TH or TCH).
